<p>在过去三个月中，4 位分析师对 Dianthus Therapeutics（纳斯达克股票代码：DNTH）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
<p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>略微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>在对 12 个月价格目标的评估中，分析师为 Dianthus Therapeutics 提供了见解，给出了 62.25 美元的平均目标，最高预估为 100.00 美元，最低预估为 40.00 美元。当前的平均目标较之前的 54.00 美元提高了 15.28%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png"/></p>
<h2>解读分析师评级：更深入的观察</h2>
<p>通过审视最近的分析师行动，我们获得了金融专家如何看待 Dianthus Therapeutics 的见解。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>上调</td>
<td>买入</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>上调</td>
<td>超越大盘</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越大盘</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 Dianthus Therapeutics 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 “超越大盘” 到 “表现不佳”。这些评级传达了对 Dianthus Therapeutics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 通过获得见解，分析师提供了对 Dianthus Therapeutics 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>为了全面了解 Dianthus Therapeutics 的市场表现，请将这些分析师评估与重要的财务指标结合起来。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 Dianthus Therapeutics 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>关于 Dianthus Therapeutics</h2>
<p>Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供具有更高选择性和效力的新型单克隆抗体，超越现有的补体疗法。该公司专注于为患有严重自身免疫和炎症疾病的患者开发下一代补体疗法。公司由一支经验丰富的生物技术和制药高管团队组成。公司的产品管线包括 DNTH103，一种皮下活性 C1s 抗体。</p>
<h3>关键指标：Dianthus Therapeutics 的财务健康状况</h3>
<p><strong>市值分析：</strong> 该公司的市值水平较低，低于行业平均水平。这表明其相对于同行的规模较小。</p>
<p><strong>收入挑战：</strong> Dianthus Therapeutics 在过去 3 个月的收入增长面临困难。截至 2025 年 6 月 30 日，该公司经历了约 <strong>-89.64%</strong> 的下降。这表明其收入出现了下降。与同行相比，该公司的收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Dianthus Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面可能面临挑战。净利润率为 <strong>-16388.08%</strong>，该公司可能在有效成本管理方面面临困难。</p>
<p><strong>股本回报率（ROE）：</strong> Dianthus Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面存在挑战。ROE 为 <strong>-10.01%</strong>，该公司可能在为股东创造最佳回报方面面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> Dianthus Therapeutics 的 ROA 低于行业标准，表明在有效利用资产方面存在困难。ROA 为 <strong>-9.38%</strong>，该公司可能在从其资产中提供令人满意的回报方面面临挑战。</p>
<p><strong>债务管理：</strong> Dianthus Therapeutics 的债务与股本比率低于行业平均水平。该比率为 <strong>0.0</strong>，表明该公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<h2>分析师评级的基础知识</h2>
<p>在银行和金融系统领域，分析师专注于特定股票或定义行业的报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度评估和评级每只股票一次。</p>
<p>一些分析师发布他们对增长预估、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供他们的意见。</p>
<p><strong>突发：华尔街下一个大动向</strong></p>
<p>Benzinga 的首席分析师刚刚识别出一只有望实现爆炸性增长的股票。这家低调的公司在重大市场变动中可能会激增 200% 以上。点击这里获取紧急详情。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

DNTH

<p>分析师最近对 Dianthus Therapeutics（NASDAQ:DNTH）提供了不同的评级，平均 12 个月目标价为 62.25 美元，较之前的目标上涨了 15.28%。主要分析师提高了他们的评级，Guggenheim 设定的目标为 100.00 美元。尽管这些前景积极，但公司面临着重大的收入挑战，过去三个月收入下降约-89.64%，净利润率为-16388.08%。Dianthus Therapeutics 专注于开发用于严重自身免疫疾病的新型单克隆抗体</p>

<p>In the preceding three months, 4 analysts have released ratings for Dianthus Therapeutics (NASDAQ: DNTH), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，4 位分析师对 Dianthus Therapeutics（纳斯达克股票代码：DNTH）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>略微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>In the assessment of 12-month price targets, analysts unveil insights for Dianthus Therapeutics, presenting an average target of $62.25, a high estimate of $100.00, and a low estimate of $40.00. This current average has increased by 15.28% from the previous average price target of $54.00.</p>
<div class="lb-trans"><p>在对 12 个月价格目标的评估中，分析师为 Dianthus Therapeutics 提供了见解，给出了 62.25 美元的平均目标，最高预估为 100.00 美元，最低预估为 40.00 美元。当前的平均目标较之前的 54.00 美元提高了 15.28%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2025/1757426464_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解读分析师评级：更深入的观察</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Dianthus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审视最近的分析师行动，我们获得了金融专家如何看待 Dianthus Therapeutics 的见解。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>上调</td>
<td>买入</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>上调</td>
<td>超越大盘</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越大盘</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 Dianthus Therapeutics 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 “超越大盘” 到 “表现不佳”。这些评级传达了对 Dianthus Therapeutics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 通过获得见解，分析师提供了对 Dianthus Therapeutics 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>To gain a panoramic view of Dianthus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了全面了解 Dianthus Therapeutics 的市场表现，请将这些分析师评估与重要的财务指标结合起来。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Dianthus Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Dianthus Therapeutics 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>About Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dianthus Therapeutics</h2>
</div><p>Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.</p>
<div class="lb-trans"><p>Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供具有更高选择性和效力的新型单克隆抗体，超越现有的补体疗法。该公司专注于为患有严重自身免疫和炎症疾病的患者开发下一代补体疗法。公司由一支经验丰富的生物技术和制药高管团队组成。公司的产品管线包括 DNTH103，一种皮下活性 C1s 抗体。</p>
</div><h3>Key Indicators: Dianthus Therapeutics's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：Dianthus Therapeutics 的财务健康状况</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值水平较低，低于行业平均水平。这表明其相对于同行的规模较小。</p>
</div><p><strong>Revenue Challenges:</strong> Dianthus Therapeutics's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately <strong>-89.64%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入挑战：</strong> Dianthus Therapeutics 在过去 3 个月的收入增长面临困难。截至 2025 年 6 月 30 日，该公司经历了约 <strong>-89.64%</strong> 的下降。这表明其收入出现了下降。与同行相比，该公司的收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Dianthus Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-16388.08%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Dianthus Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面可能面临挑战。净利润率为 <strong>-16388.08%</strong>，该公司可能在有效成本管理方面面临困难。</p>
</div><p><strong>Return on Equity (ROE):</strong> Dianthus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-10.01%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Dianthus Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面存在挑战。ROE 为 <strong>-10.01%</strong>，该公司可能在为股东创造最佳回报方面面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Dianthus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-9.38%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Dianthus Therapeutics 的 ROA 低于行业标准，表明在有效利用资产方面存在困难。ROA 为 <strong>-9.38%</strong>，该公司可能在从其资产中提供令人满意的回报方面面临挑战。</p>
</div><p><strong>Debt Management:</strong> Dianthus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.0</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Dianthus Therapeutics 的债务与股本比率低于行业平均水平。该比率为 <strong>0.0</strong>，表明该公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析师评级的基础知识</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在银行和金融系统领域，分析师专注于特定股票或定义行业的报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度评估和评级每只股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师发布他们对增长预估、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供他们的意见。</p>
</div><p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<div class="lb-trans"><p><strong>突发：华尔街下一个大动向</strong></p>
</div><p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.</p>
<div class="lb-trans"><p>Benzinga 的首席分析师刚刚识别出一只有望实现爆炸性增长的股票。这家低调的公司在重大市场变动中可能会激增 200% 以上。点击这里获取紧急详情。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

分析师对 Dianthus Therapeutics 未来发展的预期